Literature DB >> 11479570

Plant viral genes in DNA idiotypic vaccines activate linked CD4+ T-cell mediated immunity against B-cell malignancies.

N Savelyeva1, R Munday, M B Spellerberg, G P Lomonossoff, F K Stevenson.   

Abstract

DNA delivery of tumor antigens can activate specific immune attack on cancer cells. However, antigens may be weak, and immune capacity can be compromised. Fusion of genes encoding activating sequences to the tumor antigen sequence facilitates promotion and manipulation of effector pathways. Idiotypic determinants of B-cell tumors, encoded by the variable region genes, are clone-specific tumor antigens. When assembled as single-chain Fv (scFv) alone in a DNA vaccine, immunogenicity is low. Previously, we found that fusion of a sequence from tetanus toxin (fragment C; FrC) promoted anti-idiotypic protection against lymphoma and myeloma. We have now investigated an alternative fusion gene derived from a plant virus, potato virus X coat protein, a primary antigen in humans. When fused to scFv, the self-aggregating protein generates protection against lymphoma and myeloma. In contrast to scFv-FrC, protection against lymphoma is mediated by CD4+ T cells, as is protection against myeloma. Plant viral proteins offer new opportunities to activate immunity against linked T-cell epitopes to attack cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11479570     DOI: 10.1038/90816

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  17 in total

Review 1.  Vaccination strategies for lymphomas.

Authors:  Mohammed M Dar; Larry W Kwak
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

2.  Phase I clinical trial of idiotypic DNA vaccine administered as a complex with polyethylenimine to patients with B-cell lymphoma.

Authors:  A N Meleshko; N A Petrovskaya; N Savelyeva; K P Vashkevich; S N Doronina; N V Sachivko
Journal:  Hum Vaccin Immunother       Date:  2017-03-08       Impact factor: 3.452

3.  Immunogenic properties of a chimeric plant virus expressing a hepatitis C virus (HCV)-derived epitope: new prospects for an HCV vaccine.

Authors:  G Piazzolla; M Nuzzaci; C Tortorella; E Panella; A Natilla; D Boscia; A De Stradis; P Piazzolla; S Antonaci
Journal:  J Clin Immunol       Date:  2005-03       Impact factor: 8.317

4.  Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help.

Authors:  Natalia Savelyeva; Catherine A King; Ellen S Vitetta; Freda K Stevenson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-21       Impact factor: 11.205

5.  Enhancement of DNA vaccine potency through linkage of antigen to filamentous bacteriophage coat protein III domain I.

Authors:  Angel M Cuesta; Eduardo Suárez; Martin Larsen; Kim Bak Jensen; Laura Sanz; Marta Compte; Peter Kristensen; Luis Alvarez-Vallina
Journal:  Immunology       Date:  2006-04       Impact factor: 7.397

6.  Poly-beta amino ester-containing microparticles enhance the activity of nonviral genetic vaccines.

Authors:  Steven R Little; David M Lynn; Qing Ge; Daniel G Anderson; Sidharth V Puram; Jianzhu Chen; Herman N Eisen; Robert Langer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-21       Impact factor: 11.205

Review 7.  DNA vaccines to attack cancer.

Authors:  Freda K Stevenson; Christian H Ottensmeier; Peter Johnson; Delin Zhu; Sarah L Buchan; Katy J McCann; Joanne S Roddick; Andrew T King; Feargal McNicholl; Natalia Savelyeva; Jason Rice
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-03       Impact factor: 11.205

8.  Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins.

Authors:  Alejandro López-Requena; Oscar R Burrone; Michela Cesco-Gaspere
Journal:  Front Oncol       Date:  2012-11-09       Impact factor: 6.244

Review 9.  Therapeutic cancer vaccines: past, present, and future.

Authors:  Chunqing Guo; Masoud H Manjili; John R Subjeck; Devanand Sarkar; Paul B Fisher; Xiang-Yang Wang
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

10.  Trial watch: DNA vaccines for cancer therapy.

Authors:  Laura Senovilla; Erika Vacchelli; Pauline Garcia; Alexander Eggermont; Wolf Hervé Fridman; Jérôme Galon; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-04-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.